- 期刊
- OpenAccess
Diffuse Large B-Cell Lymphoma-Review
摘要
Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 30 percent of all NHL cases, involving both nodal and extra-nodal sites. Apart from distinct morphological and clinicopathological subtypes, DLBCL can be dived into molecular subtypes, Germimal Centre Subtype (GCB) and Activated B-Cell (ABC) based on gene expression profiling. IPI (International Prognostication Index) and its variants are used to prognosticate the patients. Limited stage DLBCL is primarily treated with combined modality therapy consisting of abbreviated systemic chemotherapy (three cycles), and involved field radiation therapy, whereas advanced stage disease is treated with full course of chemotherapy with recommendation of addition of novel agents (Bortezomib, Ibrutinib, Lenalidomide) in ABC type DLBCL.
延伸閱讀
- Shyung, L. R., Lin, S. C., Chang, W. H., Shih, S. C., & Kao, C. R. (2006). Diffuse Large B-Cell Lymphoma with Extensive Gastrointestinal Tract Involvement: Report of a Case. 臺灣消化醫學雜誌, 23(4), 308-314. https://doi.org/10.6557/GJT.200612_23(4).0004
- Lin, C. Y., Wu, C. H., Huang, C. H., & Huang, T. W. (2017). Diffuse Large B-cell Lymphoma Presenting with Massive Pleural Effusion. 胸腔醫學, 32(5), 226-231. https://www.airitilibrary.com/Article/Detail?DocID=10239855-201710-201709270016-201709270016-226-231
- 洪光正、楊國材、張惠媚（2000）。Primary Cutaneous Diffuse Large B Cell Lymphoma。中華皮膚科醫學雜誌，18(1)，6-13。https://www.airitilibrary.com/Article/Detail?DocID=10278117-200003-18-1-6-13-a
- Thieblemont, C., Larue, M. H. D., & Coiffier, B. (2012). Lenalidomide in Diffuse Large B-Cell Lymphoma. Advances in Hematology, 2012(), 625-632. https://doi.org/10.1155/2012/861060
- Wei, C. Y., Lam, H. B., & Chen, C. K. (2013). Diffuse Large B-Cell Lymphoma of the Nipple. 台灣癌症醫學雜誌, 29(1), 47-52. https://doi.org/10.6323/JoCRP.2013.29.1.7